(Press-News.org) Birmingham spin-out Linear Diagnostics has been awarded £1m funding to finalise the development of a rapid test for sexually transmitted infections (STIs), in partnership with the NIHR HealthTech Research Centre (HRC) in Diagnostic and Technology Evaluation and the North East Innovation Lab, part of Newcastle Hospitals.
Linear is developing a low-cost, accurate, near-patient diagnostic platform, that aims to diagnose infection from a single sample faster than any commercially available alternative.
The funding from the National Institute for Health and Care Research (NIHR) Invention for Innovation programme covers a three-year package of work, which will culminate in the first test of the technology on clinical samples in a real-world setting, and readiness for clinical trials.
Linear’s Exponential Amplification (EXPAR) technology detects bacterial DNA using an extremely fast method for amplifying the signal, which was developed and tested at the University during the COVID-19 pandemic, with results published in Proceedings of the National Academy of Sciences. The company has now shown that it can detect bacterial STIs, urinary tract infections, and viral infections including SARS-CoV-2 in as little as 5 minutes.
In recent years the company has focussed on STIs, specifically Neisseria gonorrhoeae and Chlamydia trachomatis as the emergence of multi-drug-resistant strain of the former has become a global concern.
It is here that rapid testing is essential to stop the chain of transmission, so patients can be diagnosed and start treatment within one clinic visit. While current tests may be easy to use with minimal training, existing technologies have been unable to meet the target of 20 minutes from sample to results.
The new funding will enable Linear to finalise the design of a cartridge and reader design platform and validate the platform.
Dr Jean-Louis Duprey, Head of Research and Development at Linear Diagnostics, said: “The most difficult criteria to achieve in diagnostic testing is combining rapidity with accuracy. While rapid lateral flow meets the ideal timeframe of 20 minutes to diagnosis, it struggles to meet market requirements for high sensitivity and specificity. And while Nucleic Acid Amplification Tests deliver high accuracy, samples are sent to laboratories for analysis, meaning the waiting time for results may be days. We are developing a near patient device that will overcome this conundrum.”
The HRC, hosted by Newcastle upon Tyne Hospitals NHS Foundation Trust in partnership with Newcastle University, will help to evaluate the technology.
Dr Jana Suklan, Senior Methodologist at the HRC, said: “The NIHR HRC in Diagnostic and Technology Evaluation is delighted to be collaborating with the North East Innovation Lab to support Linear Diagnostics with their exciting technology. Through reviewing clinical guidelines and speaking with healthcare professionals as well as patients and the public we will pinpoint how the platform can be developed and used so it can improve patient care.”
“Our research involves analysing unmet needs, examining current practice and identifying the most promising point in the patient pathway for implementing the technology. We will also assess the diagnostic accuracy of the test by statistically analysing data collected by the innovation lab and determine whether adopting the technology will provide value for money for the NHS through health economic modelling. Our public contributors will guide the research and ensure it meets the needs of patients, public and carers.”
John Tyson, Head of the North East Innovation Lab, part of Newcastle Hospitals, said: "We're delighted to have the opportunity to continue our collaborative work with our partner innovators to support the development and evaluation of this new exciting test. By providing access to an extensive range of clinical samples and NHS lab performance testing, we can generate the necessary evidence to move new innovative technologies to the next stage of their development or launch to mainstream use."
END
Rapid testing for sexually transmitted infections on the horizon
2025-06-05
ELSE PRESS RELEASES FROM THIS DATE:
Tech sector emissions, energy use grow with rise of AI
2025-06-05
Geneva, 5 June 2025 – Tech sector carbon emissions continued their rise in recent years, fueled by rapid advances in artificial intelligence (AI) and data infrastructure, according to Greening Digital Companies 2025.
The report, produced by the International Telecommunication Union (ITU) -- the UN agency for digital technologies -- and the World Benchmarking Alliance (WBA), tracks the greenhouse gas (GHG) emissions, energy use, and climate commitments of 200 leading digital companies as of 2023, the most recent year for which full data is available.
While the annual report calls ...
Smithsonian research reveals that probiotics slow spread of deadly disease decimating Caribbean reefs
2025-06-05
Scientists with the Smithsonian’s National Museum of Natural History have discovered that a bacterial probiotic helps slow the spread of stony coral tissue loss disease (SCTLD) in already infected wild corals in Florida. The findings, published today in the journal Frontiers in Marine Science, reveal that applying the probiotic treatment across entire coral colonies helped prevent tissue loss.
The new treatment provides a viable alternative to antibiotics, which only offer temporary protection and also run the risk of creating resistant strains of SCTLD.
“The goal of using the probiotics is to get the ...
Fungal resistance in wheat: preserving biodiversity for food security
2025-06-05
Wheat production is threatened by a major fungal disease: yellow rust. Researchers at the University of Zurich have found traditional wheat varieties from Asia that harbor several resistance-conferring genes. They may serve as a durable source of yellow rust resistance in commercial varieties in the future, highlighting the importance of genetic diversity for food security.
Yellow rust, also known as stripe rust, is caused by a fungal pathogen named Puccinia striiformis f. sp. tritici. The plant disease affects around 88% of global bread wheat production ...
’Round midnight: Late-night romance among medaka in near natural setting
2025-06-05
Osaka Metropolitan University researchers have gained clearer insights into the natural behavior of medaka, small fish that are useful as model organisms in the lab.
Specially Appointed Dr. Yuki Kondo and Professor Satoshi Awata of the Graduate School of Science conducted continuous 24-hour observations of medaka raised in an environment close to their natural habitat and verified when the fish begin their reproductive behavior.
Medaka spawning behavior in a natural environment begins around 1 a.m. and peaks between 2 a.m. and 4 a.m. In addition, courtship behavior was frequently observed ...
Why seismic waves spontaneously race inside the earth
2025-06-05
Earthquakes, volcanic eruptions, shifting tectonic plates - these are all signs that our planet is alive. But what is revealed deep inside the earth surprises laymen and scientists alike: Almost 3000 kilometres below the Earth's surface, solid rock is flowing that is neither liquid, like lava, nor brittle like solid rock. This is shown by a new study by geoscientists led by Motohiko Murakami, Professor of Experimental Mineral Physics at ETH Zurich. The study has just been published in the journal Communications Earth & Environment.
Half a ...
Survival of the greenest: Why world’s oldest organizations are surpassing young upstarts in environmental sustainability
2025-06-05
What does it take for a company to last for centuries? Ask most business analysts, and you’ll hear about innovation, financial acumen, or strategic pivots. But new research suggests another key to organizational survival: environmental sustainability. In a study recently published in Frontiers in Organizational Psychology, an international team of researchers reveals a robust link between organizations’ longevity and their commitment to environmentally sustainable business practices. The findings challenge the assumption that younger, more agile companies ...
Have female earwigs evolved their forceps as weapons in battles for mates?
2025-06-05
A new study from Toho University reveals that female earwigs exhibit a similar pattern of exaggerated forceps growth as males, suggesting that both sexes may have evolved these traits through sexual selection.
Do larger male elk have proportionally larger antlers? The answer is no. In fact, larger individuals tend to have disproportionately larger antlers—a phenomenon known as positive allometry. This pattern, where certain body parts grow disproportionately large relative to body size, is observed not only in mammals ...
Baby's microbiome may protect against childhood viral infection
2025-06-04
A baby's makeup of gut bacteria — their microbiome — which starts to form as soon as they are born, could help protect against viral infections later in childhood, a new study suggests.
As part of the largest study of UK baby microbiomes to date, researchers at the Wellcome Sanger Institute and University College London (UCL) found that babies with a specific mix of gut bacteria at one week old, which was only found in some babies born vaginally, were less likely to be hospitalised for viral lower respiratory tract infections (vLRTI) in the first two years of life.
This research, published today ...
Diabetes drug shows benefits for patients with liver disease
2025-06-04
The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.
The results show that treatment with dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) - a condition where excess fat accumulates in the liver, leading to inflammation - and liver fibrosis (a build up of scar tissue) compared ...
P2Y12 drugs may be better than aspirin to prevent heart attack and stroke in patients with coronary artery disease
2025-06-04
Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds a study published by The BMJ today.
P2Y12 inhibitors are often given to patients alongside aspirin (“dual therapy”) after percutaneous coronary intervention (PCI) - a procedure to widen or unblock a coronary artery - to help prevent cardiovascular events including heart attack and stroke.
After several months, patients ...